SILVER NANOPARTICLES ARE EFFECTIVE FOR THE TREATMENT OF CLAUDIN LOW BREAST CANCER AND OTHER MESENCHYMAL CANCERS WITH HIGH ZEB1 EXPRESSION

A woman’s lifetime risk of being diagnosed with breast cancer is approximately 1 in 8, and it is estimated that over 40,000 women will die from BC in 2017. With advances in molecular profiling, breast cancer has been divided into 5 molecular subtypes (luminal A, luminal B, HER-2 overexpressing, basal-like, and claudin-low) that have distinct genetic aberrations, morphological features, prognoses, and therapeutic responses. Therefore, breast cancer should be treated with subtype specific therapies as these may provide the greatest therapeutic benefit.

Grantor dc:publisher

Wake Forest University

Year dc:date.issued

2017

Author dc:creator

• Swanner, Jessica Lynn

• breast cancer

Language dc:language.iso

en

Handle dc:identifier.uri

http://hdl.handle.net/10339/82205

OAI identifier oai:identifier

oai:wakespace.lib.wfu.edu:10339/82205